Octreotide in the Prevention of Intra-abdominal Complications Following Elective Pancreatic Resection: A Prospective, Multicenter Randomized Controlled Trial

Archives of Surgery

Volumn 139, Issue 3, 2004, Pages 288-294

  Suc, Bertrand ^a   Msika, Simon ^b   Piccinini, Massimo ^b   Fourtanier, Gilles ^a   Hay, Jean Marie ^b   Flamant, Yves ^b   Fingerhut, Abe ^c   Fagniez, Pierre Louis ^d   Chipponi, Jacques ^e  

^a CHU RANGUEIL   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; GASTROINTESTINAL AGENT;

ABDOMINAL DISEASE; ADOLESCENT; ADULT; AGED; ANASTOMOSIS; ARTICLE; CHRONIC PANCREATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREAS FISTULA; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PANCREATICOJEJUNOSTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SURGICAL MORTALITY; CHI SQUARE DISTRIBUTION; MIDDLE AGED; NONPARAMETRIC TEST; PANCREAS DISEASE; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATIC DISEASES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 1442311642     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.139.3.288     Document Type: Article

References (33)

1. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kauffman HS, Coleman JA. One hundred and forty five consecutive pancreatico-duodenectomies without mortality. Ann Surg. 1993;217:430-438.
2. Birkmeyer J, Siewers A, Finlayson E, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128-1137.
3. Trede M, Schwall G. The complications of pancreatectomy. Ann Surg. 1988;207: 39-47.
4. Gyr KE, Meyer R. Pharmacodynamic effects of sandostatine in the gastrointestinal tract. Metabolism. 1992;9(suppl 2):17-21.
5. Buchler M, Friess H, Klempa I, et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg. 1992;163: 125-131.
6. Pederzoli P, Bassi C, Falconi M, Camboni MG. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Br J Surg. 1994;81:265-269.
7. Montorsi M, Zago M, Mosca F, et al. Efficacy of octreotide in the prevention of complication fistula after elective pancreatic resections: a prospective, controlled randomized trial. Surgery. 1995;117:26-31.
8. Friess H, Beger HG, Sulkowski U, et al. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg. 1995;82:1270-1275.
9. Lowy AM, Lee JE, Pisters PWT, et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 1997;226:632-641.
10. Yeo CJ, Cameron JL, Lillemoe KD, et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? results of a prospective randomized placebo-controlled trial. Ann Surg. 2000;232:419-429.
11. Sarr MG, for the Pancreatic Surgery Group. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003;196:556-565.
12. Ho V, Heslin MJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg. 2003;237:509-514.
13. Hamanaka Y, Nishihara K, Hamasaki T, et al. Pancreatic juice output after pancreatoduodenectomy in relation to pancreatic consistency, duct size, and leakage. Surgery. 1996;119:281-287.
14. Papachristou DN, Fortner JG. Pancreatic fistula complicating pancreatectomy for malignant disease. Br J Surg. 1981;68:238-240.
15. Yeo CH, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticofejunostomy after pancreaticoduodenectomy. Ann Surg. 1995;222:580-592.
16. Cancer Research Campaign Working Party. Trials and tribulations: thoughts on the organization of multicentre clinical studies. BMJ. 1980;281:918-920.
17. Schwartz D, Flamant R, Lellouch J. Clinical Trials. London, England: Academic Press Inc; 1980:96-98.
18. Mantel N. Chi-square test with one degree of freedom: extension of the Mantel-Haenszel procedure. J Am Stat Assoc. 1963;58:690-700.
19. Bruce J, Krukowski ZH, Al-Khairy G, et al. Systematic review of the definition and measurement of anastomotic leak after gastrointestinal surgery. Br J Surg. 2001;88:1157-1168.
20. Beger HG, Büchler M, Bittner R, Oettinger W, Roscher R. Duodenum preserving resection of the head of the pancreas in severe chronic pancreatitis. Ann Surg. 1989;209:273-278.
21. D'Andrea AA, Costantino V, Speri C, et al. Human fibrin sealant in pancreatic surgery: is it useful in preventing fistulas? a prospective randomized study. Ital J Gastroenterol. 1994;26:283-286.
22. Suc B, Msika S, Fingerhut A, et al, and the French Associations for Surgical Research. Temporary fibrin glue occlusion of the main pancreatic duct in the prevention of intra-abdominal complications after pancreatic resection. Ann Surg. 2003;237:57-65.
23. Tran K, Van Eljck C, Di Carlo V, et al. Occlusion of the pancreatic duct versus pancreaticojejunostomy. Ann Surg. 2002;236:422-428.
24. Li-Ling J, Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg. 2001; 88:190-199.
25. Buchler MW, Bassi C, Fingerhut A, Klempar I. Does pancreatic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy [letter]. Ann Surg. 2001;234:262-263.
26. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg. 1998;228:429-438.
27. Tekkis PP, Kocher HM, Bentley AJE, et al. Operative mortality rates among surgeons: comparison of POSSUM and p-POSSUM scoring systems in gastrointestinal surgery. Dis Colon Rectum. 2000;43:1528-1543.
28. Copeland G-P, Jones D, Walters M. POSSUM: a 3scoring system for surgical audit. Br J Surg. 1991;78:355-360.
29. Sato N, Yamaguchi K, Chijiiwa K, Tanaka M. Risk analysis of pancreatic fistula after pancreatic head resection. Arch Surg. 1998;133:1094-1098.
30. Yamaguchi K, Chijiiwa K, Shimizu S, Yokohata K, Tanaki M. Litmus paper helps detect potential pancreatoenterostomy leakage. Am J Surg. 1998;175:227-228.
31. Ishikawa O, Ohigashi H, Imaoka S, et al. Concomitant benefit of preoperative irradiation in preventing pancreas fistula formation after pancreaticoduodenectomy. Arch Surg. 1991;126:885-889.
32. Roder JD, Stein HJ, Böttcher KA, Busch R, Heidecke CD, Siewert R. Stented versus non-stented pancreaticojejunostomy after pancreaticoduodenectomy: a prospective study. Ann Surg. 1999;229:41-48.
33. Tashiro S, Murata E, Hiraoka T, et al. New technique for pancreaticojejunostomy using a biological adhesive. Br J Surg. 1987;74:392-394.